Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study

• 作 者: Xin-Yue Lv Hui-Guo Ding Jun-Fu
• 机 构: DepartmentofGastroenterologyandHepatology
• 出 处: 世界胃肠病学杂志:英文版
• 发表日期: 2020年2期
• 关键词: RIFAXIMIN Cirrhosis REFRACTORY ASCITES Inflammatory factors GUT MICROBIOTA METAG
• 基金项目: Supported by the State Key Projects Specialized on Infectious Diseases,No.2017ZX10203202-004 and No.2017ZX10203202003008,the Digestive Medical Coordinated Development Centre of the Beijing Municipal A

BACKGROUND Rifaximin has been shown to reduce the incidence of hepatic encephalopathy and other complications in patients with cirrhosis.However,few studies have investigated the effect of rifaximin in cirrhotic patients with refractory ascites.AIM To eva